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Children in low-resource settings carry enteric pathogens asymptomatically and are
frequently treated with antibiotics, resulting in opportunities for pathogens to be
exposed to antibiotics when not the target of treatment (i.e., bystander exposure). We
quantiﬁed the frequency of bystander antibiotic exposures for enteric pathogens and
estimated associations with resistance among children in eight low-resource settings.
We analyzed 15,697 antibiotic courses from 1,715 children aged 0 to 2 y from the
MAL-ED birth cohort. We calculated the incidence of bystander exposures and attributed exposures to respiratory and diarrheal illnesses. We associated bystander exposure
with phenotypic susceptibility of E. coli isolates in the 30 d following exposure and at
the level of the study site. There were 744.1 subclinical pathogen exposures to antibiotics per 100 child-years. Enteroaggregative Escherichia coli was the most frequently
exposed pathogen, with 229.6 exposures per 100 child-years. Almost all antibiotic exposures for Campylobacter (98.8%), enterotoxigenic E. coli (95.6%), and typical enteropathogenic E. coli (99.4%), and the majority for Shigella (77.6%), occurred when the
pathogens were not the target of treatment. Respiratory infections accounted for half
(49.9%) and diarrheal illnesses accounted for one-fourth (24.6%) of subclinical enteric
bacteria exposures to antibiotics. Bystander exposure of E. coli to class-speciﬁc antibiotics was associated with the prevalence of phenotypic resistance at the community level.
Antimicrobial stewardship and illness-prevention interventions among children in lowresource settings would have a large ancillary beneﬁt of reducing bystander selection
that may contribute to antimicrobial resistance.
antimicrobial resistance j antibiotics j bystander exposure j enteric infections j children

Antibiotic use causes selection pressure for antimicrobial resistance (AMR), a growing
global public health crisis that threatens to render antibiotics ineffective against many
high-burden infections (1). Most of the concern is placed on the development of resistance in the target pathogen of treatment (i.e., the pathogen causing the treated illness).
However, systemic treatment also results in antibiotic exposure for commensal bacteria
and pathogens carried asymptomatically at the time of treatment (2). Selective pressure
for resistance among organisms that are not the target pathogen has been called
“bystander selection” (3, 4). While the public health relevance of resistance in nonpathogenic commensal organisms is less clear, bystander selection among pathogens
carried asymptomatically at the time of treatment has direct consequences for the development of resistance in those pathogens (4). This type of selection has the potential to
promote antibiotic-resistant disease in settings where subclinical carriage of pathogens
is common.
Children in low-resource settings frequently carry enteric pathogens in the absence
of diarrheal symptoms (5). Enteroaggregative Escherichia coli (EAEC), for example, was
detected in nearly half (49%) of nondiarrheal stools collected in the ﬁrst 2 y of life in
the Etiology, Risk Factors and Interactions of Enteric Infections and Malnutrition
and the Consequences for Child Health and Development Project (MAL-ED) birth
cohort study conducted in South America, South Asia, and sub-Saharan Africa (6).
Campylobacter and Shigella, which are on the World Health Organization priority
pathogen list for concern for AMR (7), were detected in 28% (5) and 10% (8) of
nondiarrheal stools, respectively. Antibiotic treatment is also highly common in these
populations, with approximately ﬁve treatment courses per child-year observed in
MAL-ED (9). Children were treated with more than one antibiotic course per child
year for diarrhea alone (10), despite treatment guidelines that only recommend treatment for dysentery (11), which comprised less than 5% of diarrheal episodes (10). For
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Signiﬁcance
Antimicrobial resistance is a
pressing concern, and while
antibiotic stewardship
interventions are intended to limit
unnecessary antibiotic exposures,
including to asymptomatically
carried pathogens (i.e., bystander
exposure), the frequency and
characteristics of these bystander
exposures have not been well
described. We quantiﬁed the
frequency that bacterial enteric
pathogens were exposed to
antibiotics when not the target of
treatment in a study of children in
low-resource settings. Our
analysis demonstrated that almost
all enteropathogen exposures to
antibiotics occurred when the
bacteria were carried
asymptomatically, and respiratory
infections were responsible for
the largest proportion of
exposures. Interventions to
reduce antibiotic use and the
illnesses that prompt treatment
could have the ancillary beneﬁt of
reducing selection pressure for
antimicrobial resistance among
pathogens carried
asymptomatically.
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these reasons, children in low-resource settings represent a unique
population in which the burden of bystander selection on enteric
pathogens could be particularly high.
Antimicrobial stewardship interventions to prevent antibiotic
overuse and interventions to prevent illnesses that prompt antibiotic treatment, such as vaccines, could have the ancillary
beneﬁt of reducing bystander selection (12). However, the
magnitude of this potential impact is unknown. A prior study
quantiﬁed the proportion of antibiotic exposures for speciﬁc
pathogens that were not related to the treatment of that
pathogen based on modeled data from unrelated sources (3).
The observational birth cohort study, MAL-ED, provides a
unique opportunity to characterize bystander antibiotic exposure directly since testing for enteric pathogen carriage was conducted monthly in nondiarrheal stools from birth to 2 y of age,
and antibiotic use was comprehensively documented during
twice-weekly surveillance visits. Here, we aimed to quantify the
absolute frequency of bystander antibiotic exposures for enteric
bacterial pathogens carried asymptomatically at the time of
treatment among children in MAL-ED. We compared the frequency of antibiotic exposures that occurred when the bacteria
were the target pathogen to when they were bystanders and
attributed bystander exposure to speciﬁc indications for treatment. We also identiﬁed child characteristics that were associated with bystander antibiotic exposures. Finally, we assessed
the association between bystander antibiotic exposure and resistance both at the individual and the community level using
E. coli as a model organism.
Results
Among 1,715 children included in the analysis, caregivers
reported 15,697 total antibiotic courses. The majority (n =
13,629, 86.8%) of antibiotic courses had a stool sample collected and tested by qPCR with valid results within the previous 30 d (Table 1). In sensitivity analyses, 66.3 and 25.4% of

antibiotic courses had a stool sample collected and tested by
qPCR with valid results within the previous 21 and 7 d, respectively. Overall, there were 22,161 distinct exposures of enteric
pathogens to antibiotics that occurred when the pathogens
were subclinical bystanders. Approximately half (n = 12,013;
54.2%) of exposures were to drug classes that are of particular
concern for AMR (cephalosporins, ﬂuoroquinolones, macrolides,
and sulfonamides) (7). Of these classes, the highest frequency of
exposure was to macrolides (20.1%). The number of antibiotic
exposures varied by site, with relatively infrequent use in Brazil
and South Africa. While antibiotic exposures were common in
Tanzania, few were to drug classes of concern for AMR (21.2%).
Overall, for any subclinical bacterial pathogen analyzed,
there were 744.1 exposures to antibiotics per 100 child-years
(95% CI 729.1 to 760.6) (SI Appendix, Table S1). As a subclinical bystander, EAEC was exposed to antibiotics more frequently than any other pathogen, with an incidence rate of
229.6 exposures to any antibiotic per 100 child-years (95% CI
224.0 to 235.4; Fig. 1). The rate of exposure to cephalosporins
was 45.8 exposures per 100 child-years (95% CI 43.6 to 47.9),
to ﬂuoroquinolones was 10.0 exposures per 100 child-years
(95% CI 9.2 to 10.9), to macrolides was 41.5 exposures per
100 child-years (95% CI 39.7 to 43.3), and to sulfonamides
was 22.6 exposures per 100 child-years (95% CI 21.2 to 23.9).
The other bacterial pathogens were exposed at lower rates
overall: 147.2 exposures per 100 child-years (95% CI 141.7 to
153.4) for Campylobacter, 146.9 exposures per 100 child-years
(95% CI 141.7 to 152.4) for ETEC, 104.0 exposures per 100
child-years (95% CI 99.8 to 108.1) for atypical enteropathogenic E. coli (aEPEC), 70.3 exposures per 100 child-years (95%
CI 67.0 to 73.6) for typical enteropathogenic E. coli (tEPEC),
and 46.1 exposures per 100 child-years (95% CI 43.2 to 48.8)
for Shigella. The results were similar when antibiotic courses
were matched to the most recent stool within 7 d (SI Appendix,
Fig. S1) or 21 d (SI Appendix, Fig. S2) instead of 30 d in a sensitivity analysis.

Table 1. Bystander antibiotic exposures for asymptomatically carried enteric bacterial pathogens among 1,715
children enrolled in the MAL-ED cohort
Dhaka,
Fortaleza,
Bangladesh
Brazil

Vellore,
India

Children included*
210
165
227
Total antibiotic courses
3,700
224
1,740
Total linked antibiotic
3,233
148
1,537
courses†
Total bystander
6,131
125
2,700
antibiotic exposures‡
Bystander antibiotic exposures by drug class‡
Cephalosporins
1,347 (22.0) 31 (24.8)
849 (31.4)
Fluoroquinolones
621 (10.1) 0 (0.0)
159 (5.9)
Macrolides
2,532 (41.3) 5 (4.0)
226 (8.4)
Sulfonamides
28 (0.5)
6 (4.8)
262 (9.7)
Other
1,964 (32.0) 83 (66.4) 1,253 (46.4)
No. of asymptomatically carried pathogen exposures
EAEC
1,448 (23.6) 38 (30.4)
990 (36.7)
Campylobacter
1,286 (21.0) 19 (15.2)
381 (14.1)
ETEC
1,517 (24.7) 10 (8.0)
471 (17.4)
aEPEC
834 (13.6) 40 (32.0)
414 (15.3)
tEPEC
645 (10.5) 9 (7.2)
275 (10.2)
Shigella
401 (6.5)
9 (7.2)
169 (6.3)

Bhaktapur,
Nepal

Loreto,
Peru

Naushero Feroze,
Venda,
Pakistan
South Africa

227
1,051
966

194
2,051
1,905

246
4,954
4,268

1,399

3,445

5,270

Haydom,
Tanzania

Overall

237
504
395

209
1,473
1,177

1,715
15,697
13,629

332

2,759

22,161

219
80
276
137
715

(15.7)
106 (3.1)
(5.7)
156 (4.5)
(19.7) 1,001 (29.1)
(9.8)
616 (17.9)
(51.1) 1,668 (48.4)

1,780
118
262
556
2,760

(33.8)
(2.2)
(5.0)
(10.6)
(52.4)

2
3
21
27
281

(0.6)
(0.9)
(6.3)
(8.1)
(84.6)

11
6
122
448
2,178

474
283
228
274
84
56

(33.9) 1,237 (35.9)
(20.2)
491 (14.3)
(16.3)
635 (18.4)
(19.6)
538 (15.6)
(6.0)
297 (8.6)
(4.0)
247 (7.2)

1,699
1,338
845
578
528
282

(32.2)
(25.4)
(16.0)
(11.0)
(10.0)
(5.4)

138
40
41
74
20
19

(41.6)
(12.0)
(12.3)
(22.3)
(6.0)
(5.7)

813
547
629
345
236
189

(0.4)
4,345
(0.2)
1,143
(4.4)
4,445
(16.2) 2,080
(78.9) 10,902

(19.6)
(5.2)
(20.1)
(9.4)
(49.2)

(29.5)
(19.8)
(22.8)
(12.5)
(8.6)
(6.9)

(30.9)
(19.8)
(19.7)
(14.0)
(9.4)
(6.2)

6,837
4,385
4,376
3,097
2,094
1,372

Data are n or n (%). EAEC = enteroaggregative Escherichia coli. ETEC = enterotoxigenic E. coli. aEPEC = atypical enteropathogenic E. coli. tEPEC = typical enteropathogenic E. coli.
*Children were included if they had 2 complete years of follow-up with qPCR data.
†
Total linked antibiotic courses are a subset of the total antibiotic courses that could be linked to a diarrheal or surveillance stool sample in the prior 30 d.
‡
The total number of instances in which a pathogen is exposed to antibiotics. If multiple pathogens are exposed to the same course of antibiotics, each pathogen is counted. Because
an antibiotic course could include multiple drug classes, the total by drug class does not equal the total for any antibiotic. The total by subclinical pathogen equals the total for all
pathogens.
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EAEC

229.6 (224.0, 235.4)
45.8 (43.6, 47.9)
10.0 (9.2, 10.9)
41.5 (39.7, 43.3)
22.6 (21.2, 23.9)

Campylobacter

147.2 (141.7, 153.4)
30.2 (28.0, 32.4)
7.2 (6.4, 8.0)
26.6 (24.8, 28.5)
13.9 (12.7, 15.2)

ETEC

146.9 (141.7, 152.4)
28.3 (26.4, 30.1)
8.2 (7.3, 9.0)
31.7 (29.8, 33.5)
12.8 (11.6, 14.0)

aEPEC

104.0 (99.8, 108.1)
18.7 (16.9, 20.4)
5.4 (4.8, 6.1)
21.3 (19.8, 22.8)
9.6 (8.5, 10.7)
70.3 (67.0, 73.6)
15.3 (13.9, 16.8)
3.4 (2.8, 4.0)
13.3 (12.0, 14.4)
6.1 (5.3, 7.0)

tEPEC

Any antibiotic
Cephalosporins
Fluoroquinolones
Macrolides
Sulfonamides

Shigella

0

50

100

150

200

46.1 (43.2, 48.8)
9.2 (8.1, 10.4)
2.5 (2.0, 3.0)
8.9 (7.9, 9.9)
3.8 (3.1, 4.6)
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Incidence rate per 100 child years of subclinical pathogen exposures to antibiotics
Fig. 1.

Incidence rates per 100 child-years of asymptomatically carried enteric pathogen exposures to antibiotics among 1,715 children in the MAL-ED cohort.

The sites in Bangladesh (1,670.6, 95% CI 1,612.7 to
1,725.3) and Pakistan (1,243.3, 95% CI 1,193.4 to 1,298.0)
had the highest incidence rates of subclinical pathogen exposure
to antibiotics, while those in Brazil (57.3, 95% CI 47.1 to
66.7) and South Africa (89.4, 95% CI 81.2 to 97.6) had the
lowest incidence rates (SI Appendix, Table S1). Overall, macrolides and cephalosporins were the most frequently used antibiotics for all indications, with 149.3 (95% CI 137.6 to 160.7)
and 145.9 (95% CI 137.5 to 154.6) courses per 100 childyears, respectively (SI Appendix, Table S2). Macrolides were
overwhelmingly used in the Bangladesh and Peru sites and
cephalosporins in the Pakistan, Bangladesh, and India sites.
The median duration of antibiotic courses was 5 d (interquartile
range [IQR] 3 to 7 d), such that the total days of antibiotic
exposure per 100 child-years for each subclinical pathogen was
approximately 5 times the incidence rate (SI Appendix, Fig. S3).
Nearly all antibiotic exposures for Campylobacter (98.8%),
ETEC (95.6%), and tEPEC (99.4%), and the majority for
Shigella (77.6%) occurred when they were subclinical infections
and not when they were the cause of treatment (Fig. 2). When
examined by drug class, all four pathogens had a higher proportion of antibiotic exposures to cephalosporins, ﬂuoroquinolones, macrolides, and sulfonamides as subclinical infections,
except for Shigella, when exposed to ﬂuoroquinolones (44.5%
subclinical exposure versus 55.5% diarrhea treatment). A sensitivity analysis, in which antibiotic courses were matched to the
nearest stool within 21 d, instead of 30 d, yielded similar results
(SI Appendix, Fig. S4). In an additional sensitivity analysis
in which diarrhea etiology was more liberally assigned if the
pathogen was detected at any quantity (quantiﬁcation cycle
PNAS
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[Cq] <35) during diarrhea, the percentage of antibiotic exposure that occurred when the pathogen was the cause of diarrhea
increased. However, the majority of exposures still occurred
during subclinical infections: Campylobacter (86.0%), ETEC
(77.8%), tEPEC (80.9%), and Shigella (68.1%) (SI Appendix,
Fig. S5).
Together, upper respiratory infections (URIs) (37.6%) and
acute lower respiratory infections (ALRIs) (12.3%) accounted for
half (49.9%) of antibiotic courses in which bystander pathogens
were exposed (Fig. 3 and SI Appendix, Table S3). Bystander
pathogen exposure to antibiotics due to diarrheal and dysentery
illnesses combined only accounted for approximately one-fourth
(24.6%) of antibiotic exposures (with dysentery accounting for
<3% of illness for each bystander pathogen). When subset to
bystander pathogen exposures to ﬂuoroquinolones and macrolides only, URIs and ALRIs were still attributed as the reason for
antibiotic use in nearly half (45.5%) of all antibiotic courses;
however, the proportion of diarrheal and dysentery illnesses as the
reason for antibiotic use increased to more than one-third (40.7%)
(SI Appendix, Fig. S6). Upon further examination of ﬂuoroquinolone and macrolide drug classes individually, the incidence rates of
exposure due to URIs and diarrheal illnesses were nearly equivalent
across bystander pathogens (SI Appendix, Table S4).
Certain childhood characteristics were associated with lower
rates of bystander exposure to antibiotics, which may be due to
either less frequent antibiotic receipt or carriage of pathogens or
both (SI Appendix, Table S5). For every 0.5-U increase in
WAMI (access to improved water/sanitation, assets, maternal
education, and income) score, a measure of socioeconomic
status, there were 10% fewer total exposures of subclinical
https://doi.org/10.1073/pnas.2208972119
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Fig. 2. Incidence rates per 100 child-years of enteric pathogen exposures to antibiotics and the proportion of exposures that were due to diarrheal
prompting treatment versus bystander exposure among 1,715 children in the MAL-ED cohort.

bacterial pathogens to antibiotics (incidence rate ratio [IRR]
0.90, 95% CI 0.86 to 0.94). In addition, female sex (IRR 0.87,
95% CI 0.84 to 0.89), exclusive breastfeeding (IRR 0.98, 95%

CI 0.97 to 0.99), treated water (IRR 0.94, 95% CI 0.90 to
0.98), and access to an improved latrine (IRR 0.92, 95%
CI 0.89 to 0.96) were associated with fewer total exposures of

Incidence rate per 100 child years of exposures to antibiotics due to illness−specific treatment
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Fig. 3. Incidence rates per 100 child-years of enteric pathogen exposures to antibiotics and the proportion of exposures due to type of illness among 1,715
children in the MAL-ED cohort.
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subclinical bacterial pathogens to antibiotics. However, there
was no association with WAMI score (IRR 1.04, 95% CI 0.94
to 1.15) and treated water (IRR 0.96, 95% CI 0.90 to 1.02),
and the associations with improved source of drinking water
(IRR 0.78, 95% CI 0.64 to 0.94) and access to improved
latrine (IRR 0.84, 95% CI 0.76 to 0.93) strengthened when
subset to exposures to ﬂuoroquinolones or macrolides.
A total of 2,630 E. coli isolates from 505 children had antibiotic susceptibility data, and the prevalence of resistance varied
by site and drug class (Fig. 4). A total of 87% of isolates exhibited resistance to at least one antibiotic. Bystander exposure to
macrolides in the past 30 d was associated with a 29% (95%
CI 13 to 47) increase in the prevalence of macrolide resistance
in cultured E. coli isolates (SI Appendix, Table S6). Recent
bystander exposures to cephalosporins, ﬂuoroquinolones, and
sulfonamides were associated with smaller (<10%), nonsigniﬁcant increases in resistance to the corresponding drug class.
Conversely, the incidence of class-speciﬁc antibiotic exposures
at the site level were strongly correlated with the prevalence of

class-speciﬁc resistance among all isolates from that site, particularly for ﬂuoroquinolones (R = 0.91) and macrolides (R = 0.89;
Fig. 4). Macrolide exposure and prevalence of macrolide resistance
were highest in the Bangladesh and Peru sites, while ﬂuoroquinolone exposure and prevalence of ﬂuoroquinolone resistance were
highest in the Bangladesh and India sites.
Discussion
The concurrent high prevalence of subclinical enteric infections
and frequent antibiotic use among young children in lowresource settings resulted in strikingly high rates of bystander
exposure to antibiotics for bacterial enteropathogens, including
more than 10 exposures per year in some sites. The frequency
of exposure was driven largely by the prevalence of each pathogen; for example, EAEC was detected in more than half of the
nondiarrheal stools in MAL-ED (5) and accounted for the largest share of bystander exposure events. The rates of bystander
exposure varied substantially by site, with higher rates in the

Fig. 4. Associations between the incidence of bystander antibiotic exposures and the prevalence of antibiotic resistance in E. coli isolates at each of the
8 sites of the MAL-ED study. Analysis includes 153 isolates from Bangladesh, 362 isolates from Brazil, 400 isolates from India, 400 isolates from Nepal, 400
isolates from Pakistan, 311 isolates from Peru, 234 isolates from South Africa, and 370 isolates from Tanzania. Top Left: exposure to cephalosporins and
resistance to ceftriaxone; Top Right: exposure to ﬂuoroquinolones and resistance to ciproﬂoxacin; Bottom Left: exposure to macrolides and resistance to
azithromycin; Bottom Right: exposure to sulfonamides and resistance to trimethoprim/sulfamethoxazole. R denotes the Pearson correlation coefﬁcient.
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South Asian sites compared to the sub-Saharan Africa and South
American sites. These trends align with a previous analysis of
antibiotic use overall in this study (9), and can be explained by
higher rates of illness (5, 9), more frequent antibiotic treatment
of illnesses (9), and higher prevalence of asymptomatic infections
(5) in the South Asian sites. Variation in treatment frequency is
likely due to differences in treatment practices and the availability
of antibiotics across regions related to prescription requirements
and drug shortages (13–16).
For the bacterial pathogens studied, almost all of the antibiotic exposure occurred when the pathogens were not the target
of treatment. Even when diarrhea etiology was liberally deﬁned
by the detection of a pathogen at any quantity during diarrhea,
the majority of antibiotic exposures occurred outside of diarrhea episodes. Therefore, interventions to reduce selection pressure on pathogens that are of particular concern for AMR, such
as Shigella and Campylobacter, must account for exposures that
occur during subclinical infections.
Shigella was the only pathogen for which treatment of shigellosis
accounted for a substantial proportion of total antibiotic exposures
(i.e., Shigella was the target pathogen), although such treatment
accounted for only 22% of exposures of Shigella to antibiotics.
Shigella is the leading cause of dysentery (17) for which antibiotics
are indicated (11), and was the leading cause of antibiotic use
compared to other diarrhea etiologies among children in MALED (10). However, the majority of exposures to cephalosporins
and macrolides, drug classes of concern for resistant shigellosis, still
occurred when Shigella was not the cause of treatment.
Interestingly, the predictors of bystander exposure differed
from the predictors of antibiotic use overall, documented previously (9). Speciﬁcally, while higher socioeconomic status was
associated with an increase in antibiotic use overall, it was associated with fewer bystander exposures. Furthermore, exclusive
breastfeeding and improved access to water and sanitation were
protective for bystander exposures, but were not associated with
antibiotic use overall. This is likely due to fewer asymptomatic
infections among children with these characteristics (6, 8, 18)
and suggests that while antibiotic use may be more frequent in
high socioeconomic status populations, cumulative antibiotic
exposure for enteric pathogens may be driven by lower socioeconomic status populations.
These results highlight the potential ancillary beneﬁts of
antibiotic stewardship interventions for reducing selection on
bystander pathogens. An analysis of diverse data sources in the
United States suggested that preventing inappropriate antibiotic
use could prevent up to almost half of all antibiotic exposures
for some pathogen and drug combinations (19). Antibiotics are
frequently inappropriately used to treat viral causes of diarrhea
(10), and improved stewardship would reduce exposure for
bacterial enteropathogens and limit collateral effects on the
microbiota. However, because point-of-care diagnostics are
largely unavailable and clinical treatment algorithms for determining which diarrhea episodes would respond to treatment
are inadequate, efforts to reduce antibiotic prescribing for viral
diarrhea have had limited success. Interventions that prevent
the indicating illness from occurring, such as vaccines, may be
more successful at reducing antibiotic use for speciﬁc diarrhea
etiologies. For example, rotavirus vaccines were estimated to
prevent 13.6 million antibiotic-treated diarrhea episodes each
year among children in the ﬁrst 2 y of life in low- and middleincome countries (20). The protective associations observed in
this study for improved sanitation and treated drinking water
with bystander antibiotic exposure suggest that water, sanitation, and hygiene interventions may also reduce this burden.
6 of 9
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While antibiotic susceptibility testing was not possible for the
enteropathogens studied due to the application of molecular
diagnostics, the implicit assumption underlying this work is
that antibiotic exposure contributes to resistance in the pathogens studied. The association between antibiotic exposures
and resistance in the E. coli isolates informs the relevance of
bystander exposures. While the associations between recent
antibiotic exposure and resistance at the individual level were
generally small and inconsistent across drug classes, the sitelevel ecological associations between exposure and resistance
were strong, suggesting the effects of bystander exposure are
better captured at the community level. Previous work has
demonstrated associations between antibiotic use and carriage
of resistant organisms at levels spanning the individual (e.g.,
(21–23)), community (24–26), and country (27, 28), both
over time (29, 30) and across diverse geographies. Where analyzed, resistance has been linked to treatment failures necessitating the use of second-line therapies (22, 31, 32) as well as
adverse long-term outcomes and sequelae (33, 34). Detailed
characterization of enteropathogen carriage and diarrheal etiology in the small but richly sampled MAL-ED cohort provided
an opportunity to quantify bystander antibiotic exposure and
resistance from direct measurement in this study. However,
alternative designs—in particular, studies enrolling larger
cohorts—are needed to document the implications of such
exposures for rarer downstream health outcomes, including
treatment failure and adverse clinical sequelae. Such studies
remain important for measurement of the health burden of
AMR and for deﬁning the value proposition of vaccination and
stewardship interventions that may reduce the frequency of
bystander antibiotic exposure (35, 36).
The primary strength of this study was the collection of relevant pathogen infection and antibiotic use data from a longitudinal cohort, such that minimal assumptions to connect diverse
data sources were required, unlike a prior study (3). This study
was limited by the identiﬁcation of subclinical infections from
stools collected within the previous 30 d. Pathogen prevalence
at this time may under- or overestimate the pathogens present
during antibiotic treatment, especially since prevalence increased
with age for many pathogens (5). However, sensitivity analyses
using different time windows yielded similar results. The majority of antibiotic courses had a stool collected within 30 d due to
monthly sampling of nondiarrheal stools, such that extrapolation
to courses that could not be linked to a stool sample was limited
within a 30-d period. In addition, we inferred the indications for
antibiotic treatment based on the symptoms reported at the time
of treatment in lieu of a clinician’s diagnosis. Finally, the generalizability of these results may be limited given the restriction to
eight sites. Antibiotic use patterns varied by site and may have
changed since the time of the study in response to local resistance patterns, such that the incidence rates may not be applicable to other settings. Future work to transport results from this
study to a broader range of settings using more representative
survey datasets would help deﬁne the global importance of
bystander exposure. However, the evidence for the high relative
frequency of bystander exposure is likely to be consistent across
settings and time periods.
In summary, estimates of the frequency and impact of antibiotic exposure that are limited to the target pathogen of treatment largely underestimate the total selection pressure to enteric
pathogens. Pathogens that are not common causes of diarrhea in
these settings, such as EAEC, ultimately experience the highest
frequency of exposure to antibiotics due to frequent subclinical
carriage at the time of treatment. This work expands the value
pnas.org

proposition for antibiotic stewardship programs and informs
which types should be prioritized. Speciﬁcally, for example, our
results suggest that reducing antibiotic use for respiratory infections may have a larger impact on the development of resistance
in enteric pathogens than reducing antibiotic use for the treatment of enteric bacteria directly. The temporal intersection of
enteric infections and antibiotic use among children in lowresource settings results in a population in which antibiotic stewardship interventions could have an outsized impact due to the
high frequency of bystander exposure.
Materials and Methods
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Study Design and Participants. The MAL-ED study design has been previously detailed (37). The study was conducted from November 2009 through
February 2014 at eight sites: Dhaka, Bangladesh; Fortaleza, Brazil; Vellore, India;
Bhaktapur, Nepal; Loreto, Peru; Naushero Feroze, Pakistan; Venda, South Africa;
and Haydom, Tanzania. Children were enrolled from birth (younger than 17 d of
age) and were followed for 2 y. All of the sites received ethical approval from
their respective governmental, local institutional, and collaborating institutional
review boards. Written informed consent was obtained from the parent or guardian of each child.
Surveillance and Sample Collection. Twice per week, ﬁeldworkers conducted
home visits to collect information on sociodemographics, antibiotic use, presence
of illness, and feeding practices. The WAMI index was used as a marker of socioeconomic status. Diarrhea was deﬁned as three or more loose stools in a 24-h
period, and dysentery was deﬁned as at least one stool with visible blood, both
by caregiver report. URI was deﬁned previously (9) as cough or shortness of
breath by caregiver report, and ALRI was deﬁned as cough or shortness of breath
with an average respiratory rate greater than age-speciﬁc cutoffs for a rapid rate
from two measurements by ﬁeldworkers (38). Distinct illness episodes were
separated by 2 d free of the deﬁned illness.
Any antibiotic use and use of speciﬁc antibiotic drug classes were reported by
caregivers for every day of follow-up. In this analysis, we focused on any antibiotic use (i.e., all drug classes) and the use of cephalosporins, ﬂuoroquinolones,
macrolides, and sulfonamides, speciﬁcally, which are used to treat bacterial
diarrhea and are relevant for the development of resistance (11, 39). Drug
classes in the “other” category included penicillins, tetracyclines, metronidazole,
and unknown/other. Distinct antibiotic courses were deﬁned if separated by at
least two antibiotic-free days, as previously outlined (9). Nondiarrheal stool
samples were collected every month within ±7 d of the child’s birthday, and
additional stool samples were collected during each diarrhea episode. Sociodemographic characteristics were collected every 6 mo, and averaged values
across time points were included in the analysis.
Stool Testing. The QIAamp Fast DNA Stool Mini Kit (Qiagen) was used to extract
total nucleic acid from stool samples, described elsewhere (40). Quantitative PCR
(qPCR) using AgPath One Step real-time PCR kit (Thermo Fisher) via the TaqMan
Array Card platform was used to detect 29 enteropathogens (17). We used extrinsic controls (bacteriophage MS2 and phocine herpesvirus) to monitor extraction
and ampliﬁcation and extraction blank to exclude laboratory contamination. Positive detection was deﬁned at a Cq threshold <35. Bacterial pathogens that were
present in at least 5% of nondiarrheal stools were included in these analyses:
Campylobacter spp., Shigella, enterotoxigenic E. coli (ETEC), tEPEC, aEPEC,
and EAEC.
Five indole-positive, lactose-fermenting colonies (i.e., E. coli) from all of the
stool samples were cultured, pooled, and stored at 80 °C. We randomly
selected 50 children from each site who had E. coli isolates cultured from nondiarrheal stools collected at 3, 6, 9, 12, 15, 18, 21, and 24 mo of age and conducted antibiotic susceptibility testing on those isolates. Because a subset of
pooled E. coli isolates was archived at the Peru site, fewer than 8 isolates from
more than 50 children (n = 157) were included. Antibiotic susceptibility testing
was performed using the E-test for azithromycin and disk diffusion for all of
the other antibiotics. Susceptibility cutoffs were derived from the literature
for azithromycin. For all other antibiotics, susceptibility cutoffs were deﬁned by
the Clinical Laboratory Standards Institute Guidelines (SI Appendix, Table S7).
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Ceftriaxone, ciproﬂoxacin, azithromycin, and trimethoprim-sulfamethoxazole
resistance were used as indicators of class-speciﬁc resistance to cephalosporins,
ﬂuoroquinolones, macrolides, and sulfonamides, respectively.
To identify the pathogens that were carried asymptomatically at the time of antibiotic treatment, we linked each antibiotic course to the
nearest nondiarrheal or diarrheal stool sample collected within 30 d before starting the antibiotic course. Any pathogen detected in that stool was assumed to
have been exposed to the antibiotic while present asymptomatically (i.e., a
bystander exposure event occurred), unless that pathogen was the target pathogen of treatment (i.e., the cause of diarrhea prompting treatment, deﬁned
below). For courses in which a stool sample with valid pathogen data were not
available in the past 30 d, we extrapolated from courses in which data were
available by site and drug class for class-speciﬁc analyses. In sensitivity analyses,
we restricted ourselves to courses with samples collected within 21 d before
starting the antibiotic course based on an analysis of the average duration of
pathogen carriage after a diarrheal episode (41) and also within 7 d before starting the antibiotic course.
Indicating illnesses for antibiotic treatment were determined by the overlap
between antibiotic use and reported symptoms, as previously outlined (9, 10). If
an antibiotic course overlapped on any day with an ALRI, then we considered the
course to be attributed to ALRI. If the course was not due to ALRI but overlapped
with an episode of dysentery, then the course was attributed to dysentery. If the
course was not attributed to ALRI or dysentery but overlapped on any day with
diarrhea, then we considered diarrhea to be the indication for treatment. Finally,
if the course overlapped with symptoms of a URI but not the conditions above,
the course was attributed to a URI.
Target pathogens of antibiotic use for diarrhea were determined by attributing etiology to diarrheal episodes that were identiﬁed as responsible for antibiotic treatment. If multiple diarrhea episodes occurred during an antibiotic
course, then we used pathogen data from the ﬁrst diarrheal episode to deﬁne
etiology. To determine which speciﬁc enteric pathogens caused the antibiotictreated diarrhea, we constructed mixed-effects models using diarrheal and nondiarrheal stools that associated pathogen quantity with diarrhea to calculate
pathogen-speciﬁc attributable fractions for each episode (AFe), adjusting for
other pathogens, age, sex, test batch, site, and individual. Etiology-speciﬁc incidence estimates for all diarrhea episodes using these methods in comparison
with pathogen prevalence during diarrhea have been published previously (17).
We included the top 10 causes of diarrhea in MAL-ED: adenovirus 40/41, astrovirus, Campylobacter jenjui/Campylobacter coli, Cryptosporidium, norovirus, rotavirus, sapovirus, Shigella, heat-stable enterotoxigenic E. coli (ST-ETEC), and tEPEC.
A pathogen was presumed to be the causative agent of diarrhea if the AFe was
>0.5. For antibiotic courses in which a pathogen was identiﬁed as the cause of
diarrhea prompting treatment, the antibiotic course was not considered a cause
of bystander exposure to that pathogen, even if it was also detected in the stool
collected in the prior 30 d. In a sensitivity analysis, we considered a pathogen to
be the causative agent of diarrhea if detected at any quantity (Ct < 35).
To quantify bystander exposure or exposures of subclinical infections to antibiotics, we calculated the incidence rate per 100 child-years as the number of
subclinical pathogen exposures divided by the observed person-time, divided by
the proportion of antibiotic courses that could be linked to a stool within the
prior 30 d (to extrapolate to all courses). We also calculated the total number of
days of antibiotic exposure per 100 child-years for each subclinical pathogen by
summing the duration of each course. These rates were calculated for each bacterial pathogen of interest and for any bacterial pathogen. For the latter, if multiple
subclinical pathogens were exposed to the same course of antibiotics, then the
exposure was counted for each pathogen.
We then calculated the proportion of antibiotic exposures for each pathogen
that occurred as bystander exposure (i.e., when the pathogen was not considered to be the cause of antibiotic treatment) and the proportion of antibiotic
exposures that occurred when the pathogen was the cause of treatment (i.e.,
caused the diarrhea prompting treatment).
We quantiﬁed the incidence per 100 child-years and proportion of bystander
exposure events that were attributed to the treatment of diarrhea, dysentery,
URI, ALRI, and other causes for all courses of antibiotics, ﬂuoroquinolone, and
macrolide courses speciﬁcally.

Statistical Analysis.
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Finally, we estimated the associations between child characteristics and the
frequency of bystander exposure to characterize the population in which this
exposure occurs. We used Poisson regression to estimate IRRs for the total number of times that bacterial subclinical pathogens were exposed to any antibiotic.
Separately, we restricted the outcome to instances in which bacterial subclinical
pathogens were exposed to ﬂuoroquinolones or macrolides. In both instances,
we ran individual models assessing each child characteristic alone while adjusting
for site and multivariable models that included all child characteristics and site.
All of the analyses were performed overall, at each site, and for speciﬁc pathogens and drug classes. We estimated the 95% CIs for all of the estimates except
those from the Poisson models by bootstrap with 1,000 resamples. Wald intervals were used for the Poisson models.
To associate bystander antibiotic exposure with antibiotic resistance at the
individual level, we estimated the effect of class-speciﬁc antibiotic exposure in
the last 30 d on the prevalence of resistance to the same drug class in the cultured E. coli isolates. Because E. coli are ubiquitously present in stool, commensal, and therefore not the target of antibiotic treatment, all of the observed
antibiotic exposures were considered bystander exposures to E. coli. To estimate
risk ratios, we used the Poisson approximation for log-binomial regression with
generalized estimating equations to account for multiple isolates cultured from
the same child, adjusting for site, age, sex, WAMI index, and hospitalization in
the last 90 d. To compare rates of bystander exposures with antibiotic resistance
at the community level, we associated site-level incidence of class-speciﬁc antibiotic exposures with the prevalence of class-speciﬁc resistance among all of the
isolates from that site using linear regression, and we estimated the correlation
between these two variables using the Pearson correlation coefﬁcient (R). All of
the statistical analyses were performed via R software, version 4.0.2 (R Foundation for Statistical Computing).
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